Business
Thiogenesis Therapeutics Announces Investigator-Initiated Study in Nephropathic Cystinosis and Provides Program Update
San Diego, California--(Newsfile Corp. - February 2, 2026) - Thiogenesis Therapeutics, Corp. (TS...
About this update from Thiogenesis Therapeutics Corp
[{"type":"text","content":"Thiogenesis Therapeutics Announces Investigator-Initiated Study in Nephropathic Cystinosis and Provides Program UpdateSan Diego, California--(Newsfile Corp. - February 2, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) (\"Thiogenesis\" or the \"Company\"), a clinical-stage biotechnology company developing next-generation sulfur-based prodrugs for rare pediatric diseases, today provided an update on its nephropathic cystinosis program and announced a new investigator-initiated study (IIS) collaboration with Dr. Larry Greenbaum, a recognized global leader in cystinosis research, at Emory University and Children's Healthcare of Atlanta.The IIS will evaluate Thiogenesis' lead product candidate, TTI-0102, a next-generation cysteamine-based prodrug, in patients with nephropathic cystinosis to further characterize once-daily dosing, tolerability, and white blood cell (WBC) cystine control across a representative patient population. Data generated from the study are expected to support dose optimization and inform the Company's planned Phase 3 pivotal program.Dr. Greenbaum serves as Chief of Pediatric Nephrology at Children's Healthcare of Atlanta and Professor of Pediatrics at Emory University School of Medicine. He has served as a principal investigator in multiple cystinosis clinical programs and sits on the scientific and medical advisory boards of leading cystinosis patient organizations. His clinical site previously participated in the development of delayed-release cysteamine therapy, providing direct continuity with current standards of care.TTI-0102: Designed to Address Limitations of Current Cysteamine TherapiesCystinosis requires lifelong cystine-depleting therapy; however, currently approved cysteamine products, Cystagon® and Procysbi®, are associated with frequent dosing, gastrointestinal intolerance, and adherence challenges that can limit long-term disease control.TTI-0102 is a novel cysteamine-based disulfide prodrug designed to deliver sustained cysteamine exposure with lower peak plasma concentrations, enabling the potential for once-daily oral dosing.Across clinical development programs, TTI-0102 has demonstrated:Sustained 24-hour cysteamine exposure with weight-based dosingLower peak-related gastrointestinal adverse events compared to fixed dosing approachesTarget cysteamine exposure achi...